haematology

Pathways of patients with chronic haematological malignancies: a report from the UK's population-based HMRN Pathways of patients with chronic haematological malignancies: a report from the UK's population-based HMRN * Text only * * Home * Journals * * Other NIHR research * * For authors * For reviewers * About * Policies * * Accessibility * Journals LibraryNHS NIHR - National Institute for Health Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK5 Haematological Malignancy Diagnostic Service, St James’s Hospital, Leeds, UK6 Department of Haematology, Mid Yorkshire Hospitals NHS Trust, Wakefield, UK7 Department of Haematology, Castle Hill Hospital, Cottingham, UK* Corresponding author Email: eve.roman@york.ac.uk Funding: {{metadata.Funding}} {{metadata.Journal

Management of patients with diffuse intrinsic pontine glioma in Australia and New Zealand: Australian and New Zealand Children's Haematology/Oncology Group position statement Management of patients with diffuse intrinsic pontine glioma in Australia and New Zealand: Australian and New Zealand Children's Haematology/Oncology Group position statement | The Medical Journal of Australia * Basic Search administration * Hematologic diseases * History and humanities * Immune system diseases * Indigenous health * Infectious diseases * Information science * Medical education * Medical genetics * Men's health * Mental disorders * Musculoskeletal diseases * Neoplasms * Nervous system diseases * Nutritional and metabolic diseases * Occupational diseases * Otorhinolaryngologic diseases * Palliative care * Pediatric

Zanubrutinib (Brukinsa) in certain haematological malignancies Prescrire IN ENGLISH - Spotlight ''Zanubrutinib (Brukinsa°) in certain haematological malignancies'', 1 July 2024 {1}##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1}##LOC[OK]####LOC[Cancel]## Register online| Log in| My Prescrire Issue contents * Current issue * Last 12 issues * All issues Topics * Annual Prescrire Awards * Advancing * Subscribers: register online * Prescrire's other products * Free Special Edition * Sign up to receive the newsletter english.prescrire.org > Spotlight > 100 most recent > Zanubrutinib (Brukinsa°) in certain haematological malignancies SpotlightEvery month, the subjects in Prescrire’s Spotlight. 100 most recent: 1|10|20|30|40|50|60|70|80|90 Spotlight * 100 most recent * Archives Zanubrutinib (Brukinsa

Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal) Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal) Technology appraisal guidance Published: 14 September 2022 www.nice.org.uk/guidance/ta822 © NICE 2022. All rights reserved. Subject to Notice of rights (https ://www.nice.org.uk/terms-and-conditions#notice-of-rights).Contents Advice ................................................................................................................................3 Information ..................................................................................................................................3 Melphalan for haematological diseases before allogeneic

Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 2: hematologic malignancy Disseminated intravascular coagulation (DIC) associated with hematologic malignancies, particularly acute promyelocytic leukemia (APL), is characterized by marked fibrinolytic activation, which leads to severe bleeding complications. Therefore, appropriate diagnosis and management of DIC are crucial for preventing bleeding-related mortality. However, to date, no clinical guidelines have specifically addressed hematologic malignancy-associated DIC. Therefore, we developed diagnostic and management algorithms for DIC based on a systematic literature review. Notably, these guidelines recommend using the JSTH DIC diagnostic criteria (2017 version) or the former Ministry

Guideline for the investigation and management of red cell antibodies in pregnancy: A British Society for Haematology guideline 0 1 2 3 4 7 8 10 11 12 15 16 17 20 22 28 34 35 39 500 652 1500 1995 1999 2001 2011 2014 2016 2022 This guideline was compiled according to the British Society for Haematology (BSH) process at [https://b-s-h.org.uk/media/lvdbh3p5/2023-11-14-bsh-guidelines-development

A guideline for the haematological management of major haemorrhage: a British Society for Haematology Guideline A guideline for the haematological management of major haemorrhage: a British Society for Haematology Guideline

Significant haemoglobinopathies: A guideline for screening and diagnosis: A British Society for Haematology Guideline: A British Society for Haematology Guideline. Antenatal screening/testing of pregnant women should be carried out according to the guidelines of the National Health Service (NHS) Sickle Cell and Thalassaemia Screening Programme. Newborn screening and, when necessary, follow-up

The management of myelofibrosis: A British Society for Haematology Guideline

Prevention and treatment of infection in patients with an absent or hypofunctional spleen: A British Society for Haematology guideline This website utilizes technologies such as cookies to enable essential site functionality, as well as for analytics, personalization, and targeted advertising. You may change your settings at any time or accept the default settings. Privacy PolicyManage PreferencesAccept AllSkip to Article ContentSkip to Article InformationBritish Journal of HaematologyVolume 204, Issue 5 p. 1672-1686GUIDELINEFree AccessPrevention and treatment of infection in patients with an absent or hypofunctional spleen: A British Society for Haematology guidelineShamez N. Ladhani, Savio Fernandes, Mamta Garg, Ray Borrow, Simon de Lusignan, Paula H. B. Bolton-Maggs, the BSH Guidelines

Guideline for the Management of Conception and Pregnancy in Thalassaemia Syndromes: A British Society for Haematology Guideline This website utilizes technologies such as cookies to enable essential site functionality, as well as for analytics, personalization, and targeted advertising. You may change your settings at any time or accept the default settings. Privacy PolicyManage PreferencesAccept AllSkip to Article ContentSkip to Article InformationBritish Journal of HaematologyEarly ViewGUIDELINEFree AccessGuideline for the Management of Conception and Pregnancy in Thalassaemia Syndromes: A British Society for Haematology GuidelineFarrukh T. Shah, Sarah Nicolle, Mamta Garg, Shivan Pancham, Gidon Lieberman, Karen Anthony, Amma Kyei MensahFirst published: 07 May 2024 Summary This comprehensive

Guideline for laboratory diagnosis and monitoring of von Willebrand disease: A joint guideline from the United Kingdom Haemophilia Centre Doctors' Organisation and the British Society for Haematology 1714 | Br J Haematol. 2024;20 4:1714 –1731.wileyonlinelibrary.com/journal/bjhGUIDELINEBSH GuidelineGuideline for laboratory diagnosis and monitoring of von Willebrand disease: A joint guideline from Hallamshire Hospital, Sheffield, UK4Department of Haematology & the National Coagulation Centre, St. James's Hospital, Dublin, Ireland5Department of Haematology, Glasgow Royal Infirmary, Glasgow, UK6Haemophilia Unit, University Hospitals, Birmingham, UK7Katharine Dormandy Haemophilia Centre, Royal Free Hospital, London, UK8North West Genomic Laboratory Hub, Manchester University NHS Foundation Trust

Dorocubicel for treating haematological malignancies in adults requiring allogeneic HSCT Dorocubicel for treating haematological malignancies in adults requiring allogeneic HSCT - NIHR Innovation Observatory * Who we are * What we do * Our Networks * Engage * Events * News * Resources Get in touch * * A world leading Horizon Scanning Facility The NIHR Innovation Observatory is a world leading Mission * Our Values * What we do * Emerging horizon * Transitional horizon * Imminent horizon * Our Networks * Our Stakeholders * Our Work with NICE * Health & Life Sciences Ecosystem * Engage * Industry * Public Involvement * Capacity Building * Events * News * Resources * Contact 24 September 2024 Dorocubicel for treating haematological malignancies in adults requiring allogeneic HSCTHaematological

Guideline for laboratory diagnosis and monitoring of von Willebrand disease: A joint guideline from the United Kingdom Haemophilia Centre Doctors' Organisation and the British Society for Haematology 1 2 3 4 5 10 11 12 13 15 16 21 22 28 30 36 41 50 58 61 63 66 67 79 80 82 85 92 98 101 106 108 113 120 1000 This guideline updates the previous guidelines1, published on behalf of British Society for Haematology (BSH) and United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO), focussing laboratory components diagnosis monitoring. Clinical aspects will be addressed in a separate guideline. was compiled according to BSH process at https://b-s-h.org.uk/media/16732/bsh-guidance-development-process-dec-5-18.pdf. The writing group, which comprised selected members Haemostasis Thrombosis Task Force

Prevention and management of indwelling catheter-related thrombosis in sickle cell disease and thalassaemia: A British Society for Haematology Good Practice Paper 1 3 6 7 10 12 16 21 23 24 25 26 28 31 32 33 34 35 40 49 50 52 54 68 90 102 404 414 683 804 1000 1063 1979 2003 2018 This guideline was compiled according to the British Society of Haematology (BSH) process at https://b-s-h.org.uk/media

Central nervous system prophylaxis in large B-cell lymphoma: A British Society for Haematology Good Practice Paper This Good Practice Paper provides recommendations for the baseline investigation, risk stratification and use of prophylactic interventions patients with large B-cell lymphoma at central nervous system relapse. Recent evidence which has questioned role high-dose methotrexate

Measurement of heparin, direct oral anti-coagulants and other non-coumarin anti-coagulants and their effects on haemostasis assays: A British Society for Haematology Guideline onlinelibrary.wiley.comVerify you are human by completing the action below.onlinelibrary.wiley.com needs to review the security of your connection before proceeding.Ray ID: 8c72725e7bcc776fPerformance & security

Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: A British Society for Haematology Good Practice Paper 1975 Summary This good practice paper (GPP) is intended to support clinicians in assessing patient fitness for bleomycin and management of pulmonary toxicity (BPT) where it occurs. Bleomycin, originally developed

; Canadian National Advisory Committee on Immunisation; Australia and New Zealand Transplant and Cellular Therapies; British Society of Blood and Marrow Transplantation and Cellular Therapy; European Society for Blood and Marrow Transplantation; Children’s Cancer and Leukaemia Group; Haematology Society of Australia and New Zealand; American Society of Hematology; Australasian Society of Clinical COVID?19 vaccination in children and adolescents aged 5 years and older undergoing treatment for cancer and non?malignant haematological conditions COVID‐19 vaccination in children and adolescents aged 5 years and older undergoing treatment for cancer and non‐malignant haematological conditions: Australian and New Zealand Children’s Haematology/Oncology Group consensus statement | The Medical

. Hahn CN, Babic M, Brautigan PJ, Venugopal P, Phillips K, Dobbins J, et al. Australian Familial Haematological Cancer Study - Findings from 15 Years of Aggregated Clinical, Genomic and Transcriptomic Data. Blood. 2019;134:1439. 7 4. DeZern AE, Dalton WB. How low risk are low risk myelodysplastic syndromes? Expert Review of Hematology. 2022;15(1):15-24. 11 provided. The Applicant Genetic testing for variants associated with haematological malignancies 1 Medical Services Advisory Committee (MSAC) Public Summary Document Application No. 1684 – Genetic testing for variants associated with haematological malignancies Applicant: Royal Australasian College of Pathologists Date of MSAC consideration: 24-25 November 2022 Context for decision: MSAC makes its advice